Publication Date:
Sun, 2004-11-21 03:00
LONDON, 21 November 2004 — Abdullah Al-Bajadi Al-Shahrani, executive president of the Riyadh-based Arabian Recab Trading Co., recently signed a contract to acquire 30 percent of the share capital of Amenni, which is a pharmaceutical and nutraceutical holding company with three subsidiaries. The subsidiaries are Iceni Animal HealthCare, Omni Nutraceuticals and Bionovate R&D, with distribution throughout Europe and the United States.
The group specializes in the development, patenting and marketing of naturally sourced products that help in reducing the severity of some of the world’s major diseases. Current products treat asthma, arthritis and heart disease. The group also has a very strong new product pipeline.
Main category:
Old Categories: